Literature DB >> 21160995

A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.

Masako Nishimura1.   

Abstract

Biliary tract cancers (BTC) are relatively rare tumors, and the prognosis is extremely poor. There has been no standard chemotherapy for advanced BTC. However, recently, gemcitabine (GEM) have been used against BTC as the most active agent, and promising response rates and overall survival times with tolerable drug toxicities have been observed. In this article, two cases of advanced intrahepatic cholangiocarcinoma and unresectable metastatic gallbladder (GB) cancer are reported. They were treated with hepatic arterial infusion (HAI) chemotherapy using a combination of GEM and cisplatin, along with the systemic administration of GEM. As a consequence, multiple liver tumors, the GB cancer and metastatic lymph nodes regressed without severe drug toxicities, and favorable results (the overall survival times were 16 and 14 mo, respectively) were achieved. In conclusion, HAI therapy using GEM combined with cisplatin may be a useful and well-tolerated option for advanced BTC, especially in cases where multiple liver metastases are detected.

Entities:  

Keywords:  Cisplatin; Gallbladder cancer; Gemcitabine; Hepatic arterial infusion; Intrahepatic cholangiocarcinoma

Year:  2010        PMID: 21160995      PMCID: PMC2999280          DOI: 10.4254/wjh.v2.i5.192

Source DB:  PubMed          Journal:  World J Hepatol


  20 in total

1.  Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.

Authors:  Maurizio Cantore; Andrea Mambrini; Giammaria Fiorentini; Carla Rabbi; Donatella Zamagni; Roberto Caudana; Cristina Pennucci; Franco Sanguinetti; Mirko Lombardi; Nicola Nicoli
Journal:  Cancer       Date:  2005-04-01       Impact factor: 6.860

2.  Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.

Authors:  S Thongprasert; S Napapan; C Charoentum; S Moonprakan
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

3.  Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.

Authors:  Thomas J Vogl; Wolfram Schwarz; Katrin Eichler; Kathrin Hochmuth; Renate Hammerstingl; Ursula Jacob; Albert Scheller; Stephan Zangos; Matthias Heller
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-21       Impact factor: 4.553

4.  Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.

Authors:  Ali I Shamseddine; Mohammad J Khalifeh; Fadi H Mourad; Aref A Chehal; Aghiad Al-Kutoubi; Jaber Abbas; Mohammad Z Habbal; Lida A Malaeb; Anwar B Bikhazi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

6.  Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.

Authors:  Mazin A Moufarij; Don R Phillips; Carleen Cullinane
Journal:  Mol Pharmacol       Date:  2003-04       Impact factor: 4.436

7.  Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.

Authors:  J J Knox; D Hedley; A Oza; L L Siu; G R Pond; M J Moore
Journal:  Ann Oncol       Date:  2004-05       Impact factor: 32.976

8.  Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.

Authors:  Niraj J Gusani; Fady K Balaa; Jennifer L Steel; David A Geller; J Wallis Marsh; Albert B Zajko; Brian I Carr; T Clark Gamblin
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

9.  Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Authors:  Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2007-06-29       Impact factor: 3.199

10.  A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.

Authors:  Renuka V Iyer; John Gibbs; Boris Kuvshinoff; Marwan Fakih; James Kepner; Nancy Soehnlein; David Lawrence; Milind M Javle
Journal:  Ann Surg Oncol       Date:  2007-08-19       Impact factor: 5.344

View more
  4 in total

1.  Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study.

Authors:  Ting Zhang; Xu Yang; Xiaobo Yang; Kanglian Zheng; Yanyu Wang; Yunchao Wang; Xinting Sang; Xin Lu; Yiyao Xu; Xiaodong Wang; Haitao Zhao
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.

Authors:  Junro Kataoka; Hidenori Shiraha; Shigeru Horiguchi; Hiroaki Sawahara; Daisuke Uchida; Teruya Nagahara; Masaya Iwamuro; Hiroki Morimoto; Yasuto Takeuchi; Kenji Kuwaki; Hideki Onishi; Shinichiro Nakamura; Akinobu Takaki; Kazuhiro Nouso; Takahito Yagi; Kazuhide Yamamoto; Hiroyuki Okada
Journal:  Oncol Rep       Date:  2016-03-16       Impact factor: 3.906

3.  Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma.

Authors:  Ming-Chun Ma; Yen-Yang Chen; Shau-Hsuan Li; Yu-Fan Cheng; Chih-Chi Wang; Tai-Jan Chiu; Sung-Nan Pei; Chien-Ting Liu; Tai-Lin Huang; Chen-Hua Huang; Yu-Li Su; Yen-Hao Chen; Sheng-Nan Lu; Kun-Ming Rau
Journal:  ScientificWorldJournal       Date:  2014-05-22

4.  Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection.

Authors:  Cheng Chen; Wenming Feng; Yinyuan Zheng; Ying Bao; Min Feng
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.